Neuromolecular, Inc.
Records under this name other than the patents Neuromolecular, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,209 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject Formerly held Term ended Term ended Jul 18, 2026 · High confidence | Term ended | Term ended Jul 18, 2026 | High confidence |
| US 7,619,007 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject Term ended Ended no later than Nov 22, 2025 · Medium confidence | Term ended | Ended no later than Nov 22, 2025 | Medium confidence |
| US 8,173,708 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject Formerly held Term ended Term ended Nov 22, 2025 · Medium confidence | Term ended | Term ended Nov 22, 2025 | Medium confidence |
| US 8,283,379 | Methods and Compositions for the Treatment of Cns-Related Conditions Term ended Term ended Nov 22, 2025 · Medium confidence | Term ended | Term ended Nov 22, 2025 | Medium confidence |
| US 8,293,794 | Methods and Compositions for the Treatment of Cns-Related Conditions Term ended Term ended Nov 22, 2025 · Medium confidence | Term ended | Term ended Nov 22, 2025 | Medium confidence |
| US 8,329,752 | Composition for Administering an Nmda Receptor Antagonist to a Subject Formerly held Term ended Ended no later than Nov 22, 2025 · Medium confidence | Term ended | Ended no later than Nov 22, 2025 | Medium confidence |
| US 8,338,485 | Compositions for the Treatment of Cns-Related Conditions Formerly held Term ended Ended no later than Nov 22, 2025 · Medium confidence | Term ended | Ended no later than Nov 22, 2025 | Medium confidence |
| US 8,338,486 | Methods for the Treatment of Cns-Related Conditions Formerly held Term ended Ended no later than Nov 22, 2025 · Medium confidence | Term ended | Ended no later than Nov 22, 2025 | Medium confidence |
| US 8,362,085 | Method for Administering an Nmda Receptor Antagonist to a Subject Formerly held Term ended Ended no later than Nov 22, 2025 · Medium confidence | Term ended | Ended no later than Nov 22, 2025 | Medium confidence |
| US 8,426,472 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject Formerly held Term ended Term ended Nov 22, 2025 · Medium confidence | Term ended | Term ended Nov 22, 2025 | Medium confidence |